文献速递中医内科中药与中成药合理使用中医康复

瘀血痹片缓解神经病理性疼痛的药理机制:网络药理学、分子对接、16S rRNA测序与代谢组学研究

Pharmacological mechanisms of Yuxuebi tablet in alleviating neuropathic pain: Insights from network pharmacology, molecular docking, 16S rRNA sequencing, and metabolomics.
PubMed 文献 · Phytomedicine · 2026-04-02

本研究旨在评估瘀血痹片(YXBT)对慢性压迫性损伤(CCI)诱导的神经病理性疼痛(NP)大鼠的镇痛作用并阐明其分子机制。采用网络药理学与分子对接预测关键靶点,建立CCI大鼠模型,通过行为学、组织病理学、炎症因子检测及qRT-PCR和免疫印迹验证通路,并整合16S rRNA测序与代谢组学分析肠道菌群和血清代谢物。结果表明YXBT可提高CCI大鼠的PWT和PWL,促进坐骨神经和DRG损伤修复,降低腰段脊髓IL1β、IL6、TNFα水平,抑制EGFR/PI3K/AKT通路激活,并逆转磷脂、氨基酸、肉碱和胆汁酸代谢紊乱,调节肠道菌群组成与相对丰度。

要点

  • YXBT可提高CCI大鼠的PWT和PWL,减轻神经病理性疼痛。
  • YXBT降低腰段脊髓IL1β、IL6、TNFα水平并抑制EGFR/PI3K/AKT通路。
  • YXBT调节肠道菌群及磷脂、氨基酸、肉碱、胆汁酸代谢途径。

核心结论

  • 本研究系统证明了YXBT对神经病理性疼痛的治疗作用并阐明了其药理机制。
  • YXBT通过调节肠道菌群、代谢途径及相关代谢物,为其治疗NP提供了科学依据。

研究设计与样本

  • 采用网络药理学和分子对接预测YXBT治疗NP的关键靶点。
  • 建立CCI刺激的NP大鼠模型,评估YXBT的治疗效果。
  • 通过qRT-PCR和免疫印迹验证YXBT作用的信号通路。
  • 整合16S rRNA测序和代谢组学探究YXBT对CCI大鼠肠道菌群和血清代谢物的调控。

主要发现

  • YXBT治疗显著增加CCI大鼠的PWT和PWL。
  • YXBT促进坐骨神经和DRG损伤修复。
  • YXBT降低腰段脊髓IL1β、IL6、TNFα水平并抑制EGFR/PI3K/AKT信号通路激活。
  • YXBT逆转磷脂、氨基酸、肉碱和胆汁酸途径的代谢紊乱。
  • YXBT调节肠道菌群的组成和相对丰度。

临床怎么用

  • YXBT可能作为神经病理性疼痛的潜在治疗选择,尤其适用于伴有肠道菌群或代谢紊乱的患者。
  • 临床可关注YXBT对脊髓炎症因子及EGFR/PI3K/AKT通路的调控作用。

局限性

  • 目前尚无确切的临床研究证实YXBT治疗神经病理性疼痛的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yuxuebi Tablet (YXBT) is a traditional Chinese patent medicine and is mainly used to treat joint swelling and pain associated with rheumatic arthritis and osteoarthritis. However, to date, no definitive clinical studies have confirmed the efficacy of YXBT for treating neuropathic pain (NP). PURPOSE: To assess the analgesic effects of YXBT on chronic constriction injury (CCI)-stimulated NP in rats and to elucidate the underlying molecular mechanism. METHODS: Network pharmacology and molecular docking were employed to predict the key targets of YXBT in the treatment of NP. A CCI-stimulated rat model of NP was established, and the therapeutic effects of YXBT were evaluated using multiple parameters, including paw withdrawal threshold (PWT), paw withdrawal latency (PWL), histopathological assessment of the sciatic nerve and dorsal root ganglion (DRG), and levels of spinal inflammatory cytokines. The signaling pathways underlying YXBT's effects were further validated by qRT-PCR and immunoblotting. In addition, 16S rRNA sequencing and metabolomics were integrated to investigate the regulatory impact of YXBT on gut microbiota composition and serum metabolites in CCI rats, thereby elucidating its potential mechanisms against NP. RESULTS: YXBT treatment significantly increased PWT and PWL in CCI rats, promoted repair of sciatic nerves and DRG damage, reduced the levels of IL1β, IL6, and TNFα in the lumbar spinal cord, and suppressed activation of the EGFR/PI3K/AKT signaling pathway. Moreover, YXBT reversed metabolic disturbances in phospholipid, amino acid, carnitine, and bile acid pathways, while also modulating the composition and relative abundance of the gut microbiota. CONCLUSION: This study systematically demonstrated the therapeutic effects of YXBT in NP and elucidated its underlying pharmacological mechanism. By regulating gut microbiota, metabolic pathways, and associated metabolites, YXBT provides a scientific basis for its application in NP treatment.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Cheng X, Yang Q, Yuan X, et al. Pharmacological mechanisms of Yuxuebi tablet in alleviating neuropathic pain: Insights from network pharmacology, molecular docking, 16S rRNA sequencing, and metabolomics. Phytomedicine. 2026. PMID: 41956022. doi:10.1016/j.phymed.2026.158150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。